“A Prospective, Multi-Center Clinical Utility Study Demonstrates That the 40-Gene Expression Profile (40-GEP) Test Impacts Clinical Management for Medicare-Eligible Patients With High-Risk Cutaneous Squamous Cell Carcinoma (cSCC)”. 2022. SKIN The Journal of Cutaneous Medicine 6 (6): 482-96. https://doi.org/10.25251/skin.6.6.5.